CBER Should Develop Industry Guidance For Pre-Submission Meetings - HIMA
This article was originally published in The Gray Sheet
Executive Summary
FDA's Center for Biologics Evaluation and Research should develop a guidance establishing a framework for pre-submission meetings between CBER and device manufacturers, the Health Industry Manufacturers Association says.